Literature DB >> 21119085

Mitochondrial dysfunction in autism.

Cecilia Giulivi1, Yi-Fan Zhang, Alicja Omanska-Klusek, Catherine Ross-Inta, Sarah Wong, Irva Hertz-Picciotto, Flora Tassone, Isaac N Pessah.   

Abstract

CONTEXT: Impaired mitochondrial function may influence processes highly dependent on energy, such as neurodevelopment, and contribute to autism. No studies have evaluated mitochondrial dysfunction and mitochondrial DNA (mtDNA) abnormalities in a well-defined population of children with autism.
OBJECTIVE: To evaluate mitochondrial defects in children with autism. DESIGN, SETTING, AND PATIENTS: Observational study using data collected from patients aged 2 to 5 years who were a subset of children participating in the Childhood Autism Risk From Genes and Environment study in California, which is a population-based, case-control investigation with confirmed autism cases and age-matched, genetically unrelated, typically developing controls, that was launched in 2003 and is still ongoing. Mitochondrial dysfunction and mtDNA abnormalities were evaluated in lymphocytes from 10 children with autism and 10 controls. MAIN OUTCOME MEASURES: Oxidative phosphorylation capacity, mtDNA copy number and deletions, mitochondrial rate of hydrogen peroxide production, and plasma lactate and pyruvate.
RESULTS: The reduced nicotinamide adenine dinucleotide (NADH) oxidase activity (normalized to citrate synthase activity) in lymphocytic mitochondria from children with autism was significantly lower compared with controls (mean, 4.4 [95% confidence interval {CI}, 2.8-6.0] vs 12 [95% CI, 8-16], respectively; P = .001). The majority of children with autism (6 of 10) had complex I activity below control range values. Higher plasma pyruvate levels were found in children with autism compared with controls (0.23 mM [95% CI, 0.15-0.31 mM] vs 0.08 mM [95% CI, 0.04-0.12 mM], respectively; P = .02). Eight of 10 cases had higher pyruvate levels but only 2 cases had higher lactate levels compared with controls. These results were consistent with the lower pyruvate dehydrogenase activity observed in children with autism compared with controls (1.0 [95% CI, 0.6-1.4] nmol × [min × mg protein](-1) vs 2.3 [95% CI, 1.7-2.9] nmol × [min × mg protein](-1), respectively; P = .01). Children with autism had higher mitochondrial rates of hydrogen peroxide production compared with controls (0.34 [95% CI, 0.26-0.42] nmol × [min × mg of protein](-1) vs 0.16 [95% CI, 0.12-0.20] nmol × [min × mg protein](-1) by complex III; P = .02). Mitochondrial DNA overreplication was found in 5 cases (mean ratio of mtDNA to nuclear DNA: 239 [95% CI, 217-239] vs 179 [95% CI, 165-193] in controls; P = 10(-4)). Deletions at the segment of cytochrome b were observed in 2 cases (ratio of cytochrome b to ND1: 0.80 [95% CI, 0.68-0.92] vs 0.99 [95% CI, 0.93-1.05] for controls; P = .01).
CONCLUSION: In this exploratory study, children with autism were more likely to have mitochondrial dysfunction, mtDNA overreplication, and mtDNA deletions than typically developing children.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21119085      PMCID: PMC3915058          DOI: 10.1001/jama.2010.1706

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  38 in total

1.  Mitochondrial DNA copy number is proportional to total cell DNA under a variety of growth conditions.

Authors:  J W Shay; D J Pierce; H Werbin
Journal:  J Biol Chem       Date:  1990-09-05       Impact factor: 5.157

2.  Mitochondrial DNA molecules and virtual number of mitochondria per cell in mammalian cells.

Authors:  E D Robin; R Wong
Journal:  J Cell Physiol       Date:  1988-09       Impact factor: 6.384

3.  Mitochondrial gene expression in mammalian striated muscle. Evidence that variation in gene dosage is the major regulatory event.

Authors:  R S Williams
Journal:  J Biol Chem       Date:  1986-09-15       Impact factor: 5.157

4.  Diagnostic uses of the Vineland Adaptive Behavior Scales.

Authors:  S S Sparrow; D V Cicchetti
Journal:  J Pediatr Psychol       Date:  1985-06

Review 5.  Pyridine nucleotides and rate control.

Authors:  H A Krebs
Journal:  Symp Soc Exp Biol       Date:  1973

6.  Investigation of mitochondrial metabolism in small human skeletal muscle biopsy specimens. Improvement of preparation procedure.

Authors:  J C Fischer; W Ruitenbeek; A M Stadhouders; J M Trijbels; R C Sengers; A J Janssen; J H Veerkamp
Journal:  Clin Chim Acta       Date:  1985-01-15       Impact factor: 3.786

7.  Pyruvate dehydrogenase deficiency: clinical and biochemical diagnosis.

Authors:  L De Meirleir; W Lissens; R Denis; J L Wayenberg; A Michotte; J M Brucher; E Vamos; E Gerlo; I Liebaers
Journal:  Pediatr Neurol       Date:  1993 May-Jun       Impact factor: 3.372

8.  Clinical spectrum, morbidity, and mortality in 113 pediatric patients with mitochondrial disease.

Authors:  Fernando Scaglia; Jeffrey A Towbin; William J Craigen; John W Belmont; E O'Brian Smith; Stephen R Neish; Stephanie M Ware; Jill V Hunter; Susan D Fernbach; Georgirene D Vladutiu; Lee-Jun C Wong; Hannes Vogel
Journal:  Pediatrics       Date:  2004-10       Impact factor: 7.124

9.  Oxidative stress-related alteration of the copy number of mitochondrial DNA in human leukocytes.

Authors:  Chin-San Liu; Ching-Shan Tsai; Chen-Ling Kuo; Haw-Wen Chen; Chong-Kuei Lii; Yi-Shing Ma; Yau-Huei Wei
Journal:  Free Radic Res       Date:  2003-12

10.  A pattern of accumulation of a somatic deletion of mitochondrial DNA in aging human tissues.

Authors:  G A Cortopassi; D Shibata; N W Soong; N Arnheim
Journal:  Proc Natl Acad Sci U S A       Date:  1992-08-15       Impact factor: 11.205

View more
  172 in total

Review 1.  Networking in autism: leveraging genetic, biomarker and model system findings in the search for new treatments.

Authors:  Jeremy Veenstra-VanderWeele; Randy D Blakely
Journal:  Neuropsychopharmacology       Date:  2011-09-21       Impact factor: 7.853

2.  Examining autism spectrum disorders by biomarkers: example from the oxytocin and serotonin systems.

Authors:  Elizabeth Hammock; Jeremy Veenstra-VanderWeele; Zhongyu Yan; Travis M Kerr; Marianna Morris; George M Anderson; C Sue Carter; Edwin H Cook; Suma Jacob
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2012-05-26       Impact factor: 8.829

3.  Mitochondrial Citrate Transporter-dependent Metabolic Signature in the 22q11.2 Deletion Syndrome.

Authors:  Eleonora Napoli; Flora Tassone; Sarah Wong; Kathleen Angkustsiri; Tony J Simon; Gyu Song; Cecilia Giulivi
Journal:  J Biol Chem       Date:  2015-07-28       Impact factor: 5.157

4.  AMPD1 functional variants associated with autism in Han Chinese population.

Authors:  Lusi Zhang; Jianjun Ou; Xiaojuan Xu; Yu Peng; Hui Guo; Yongcheng Pan; Jingjing Chen; Tianyun Wang; Hao Peng; Qiong Liu; Di Tian; Qian Pan; Xiaobin Zou; Jingping Zhao; Zhengmao Hu; Kun Xia
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2014-08-26       Impact factor: 5.270

Review 5.  Mitochondrial Aspartate/Glutamate Carrier SLC25A12 and Autism Spectrum Disorder: a Meta-Analysis.

Authors:  Yuta Aoki; Samuele Cortese
Journal:  Mol Neurobiol       Date:  2015-02-10       Impact factor: 5.590

Review 6.  Mitochondrial dysfunction can connect the diverse medical symptoms associated with autism spectrum disorders.

Authors:  Richard E Frye; Daniel A Rossignol
Journal:  Pediatr Res       Date:  2011-05       Impact factor: 3.756

7.  Substantial problems with measuring brain mitochondrial dysfunction in autism spectrum disorder using magnetic resonance spectroscopy.

Authors:  Daniel A Rossignol; Richard E Frye
Journal:  J Autism Dev Disord       Date:  2012-04

Review 8.  Deficits in bioenergetics and impaired immune response in granulocytes from children with autism.

Authors:  Eleonora Napoli; Sarah Wong; Irva Hertz-Picciotto; Cecilia Giulivi
Journal:  Pediatrics       Date:  2014-05       Impact factor: 7.124

9.  Open-Label Allopregnanolone Treatment of Men with Fragile X-Associated Tremor/Ataxia Syndrome.

Authors:  J Y Wang; A M Trivedi; N R Carrillo; J Yang; A Schneider; C Giulivi; P Adams; F Tassone; K Kim; S M Rivera; N Lubarr; C-Y Wu; R W Irwin; R D Brinton; J M Olichney; M A Rogawski; R J Hagerman
Journal:  Neurotherapeutics       Date:  2017-10       Impact factor: 7.620

10.  Preeclampsia, placental insufficiency, and autism spectrum disorder or developmental delay.

Authors:  Cheryl K Walker; Paula Krakowiak; Alice Baker; Robin L Hansen; Sally Ozonoff; Irva Hertz-Picciotto
Journal:  JAMA Pediatr       Date:  2015-02       Impact factor: 16.193

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.